Quantcast
Last updated on April 17, 2014 at 13:13 EDT

ESTEVE Communicates its R&D Through a New Interactive Platform

July 11, 2012

BARCELONA, July 12, 2012 /PRNewswire/ –

This site is part of the http://www.esteve.com
[http://www.esteve.com/investigacion-desarrollo ] corporate web portal

        - ESTEVE's new website provides consise and updated information on its
          projects under development. Among these is the S1RA (Sigma-1 Receptor Antagonist), a
          new chemical entity, presently in Clinical Phase II, for treating several types of
          pain
        - In addition to defining the Company's main lines of research, this new website
          also discloses the Company's different and innovative models of collaboration

ESTEVE announces the launch of a new website [http://www.esteve.es/EsteveFront/IDI.do
] (http://www.esteve.es/EsteveFront/IDI.do?lng=en) with the purpose of communicating
the Company’s R&D and the innovative models of collaboration currently implemented. Newly
formatted and fully integrated in the http://www.esteve.com web portal, this site
reinforces the commitment of ESTEVE to R&D with emphasis on a solid strategy to provide
new therapeutic solutions for unmet medical needs in highly prevalent diseases of high
social impact.

With its primary focus in analgesia, ESTEVE is developing innovative therapies for
pain. Two projects are presently undergoing clinical development for the treatment of
neuropathic pain and moderate to severe acute and chronic pain.

One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist
that offers a new approach and a new mechanism of action in a field (neuropathic pain)
strongly in need of novel, more effective and safer therapies.

The new website also describes the innovative partnering strategy in R&D as well as
ESTEVE’s network of excellence built through unique collaborative models. This network
includes different types of alliances, from public-private partnerships -such as the
HIVACAT program to develop an effective vaccine against HIV and the Sanfilippo project to
develop a treatment for a rare childhood disease- to R&D consortiums such as Neogenius for
pain research.

One of the key features of this site is its attractively designed interface for
portfolio presentation, which includes the various ongoing R&D programs, i.e. in-house
projects in analgesia, projects in collaboration with other centers or companies, and
in-licensed projects.

With language and information customized for each audience, this new website provides
specific information for scientists, healthcare providers, industry partners, patients and
other stakeholders.

About ESTEVE

ESTEVE is a leading chemical-pharmaceutical group in Spain and has a strong
international presence. Ever since its foundation in 1929, ESTEVE has been firmly
committed to excellence and has been using its best efforts to promote health and improve
people’s quality of life.

SOURCE ESTEVE


Source: PR Newswire